ATLAS ACS 2-TIMI 51 is a phase III, multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating an oral, direct factor Xa inhibitor (rivaroxaban) in subjects following an acute coronary syndrome. Subjects are to receive low-dose aspirin therapy (75 to 100 mg/day), and enrollment will be stratified based upon the intent of the investigator to administer a thienopyridine [Stratum 1 (aspirin only) and Stratum 2 (aspirin plus a thienopyridine)]. Two different doses of rivaroxaban will be tested: 2.5 mg twice a day and 5.0 mg twice a day.


Key Study Publications

Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FW, Gibson CM; ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366:9-19. Abstract